MinorGabapentinoids (antiepileptics)×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Pregabalin undergoes negligible metabolism: less than 2% of a dose appears in the urine as metabolites and the rest is excreted unchanged by the kidneys. It does not bind to plasma proteins and does not inhibit drug metabolism in vitro. According to its SmPC, it is unlikely to cause or be subject to pharmacokinetic interactions (pregabalin SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2). About two thirds of a rivaroxaban dose is metabolised by CYP3A4, CYP2J2 and CYP-independent pathways, and one third is excreted unchanged by the kidneys through active secretion. In vitro, rivaroxaban is a substrate of P-gp and BCRP (rivaroxaban SmPC, European Medicines Agency, EMA, section 5.2). Its exposure is changed by strong inhibitors of CYP3A4 and P-gp and by strong CYP3A4 inducers (rivaroxaban SmPC, EMA, section 4.5), and pregabalin is not one of them.
Symptoms
The documents describe no symptoms caused by this combination. Pregabalin causes dizziness and somnolence, which can increase the risk of falls in older people. Loss of consciousness and confusion have been reported after marketing (pregabalin SmPC, European Medicines Agency, EMA, section 4.4). Like other anticoagulants, rivaroxaban increases the risk of bleeding, and people taking it are carefully observed for signs of bleeding (rivaroxaban SmPC, EMA, section 4.4).
Management
According to the documents, the combination is acceptable and no dose change of rivaroxaban or pregabalin is needed. Neither document names the pair, and pregabalin does not alter the metabolism of other drugs (pregabalin and rivaroxaban SmPCs, European Medicines Agency, EMA, section 4.5). People taking pregabalin are advised to be careful until they know how it affects them. In renal impairment, the pregabalin dose is reduced according to creatinine clearance (pregabalin SmPC, EMA, sections 4.2, 4.4 and 5.2). Rivaroxaban is used with caution in conditions with an increased risk of bleeding and is stopped if severe haemorrhage occurs (rivaroxaban SmPC, EMA, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- EMA: Xarelto (rivaroxabán) – ficha técnica en CIMA (2026)– AEMPS CIMA, Xarelto 20 mg comprimidos recubiertos con película, nº registro 08472018 (EU/1/08/472), secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Pregabalina (EU/1/04/279), secciones 4.4 y 4.5 (2024)– EMA, ficha técnica de Lyrica en CIMA (nº registro 104279015), revisión del texto 05/2024, secciones 4.4 y 4.5